Systemic type 2 inflammation encompassing T helper 2 (TH2)-type responses is emerging
as a unifying feature of both classically defined allergic diseases, such as asthma, and a …

There is poor agreement on definitions of different phenotypes of preschool wheezing
disorders. The present Task Force proposes to use the terms episodic (viral) wheeze to …

Background As asthma symptoms worsen, patients typically rely on short-acting β2-agonist
(SABA) rescue therapy, but SABAs do not address worsening inflammation, which leaves …

Introduction Consensus definitions for clinical remission and super-response were recently
established for severe asthma. Benralizumab is an interleukin-5 (IL-5) receptor α-directed …

Background Novel biologic therapies have revolutionised the management of severe
asthma with more ambitious treatment aims. Here we analyse the definition of clinical …

Background In adults with mild asthma, a combination of an inhaled corticosteroid with a fast-
onset long-acting β-agonist (LABA) used as reliever monotherapy reduces severe …

Background Despite inhaled corticosteroid plus long-acting β 2-agonist (ICS/LABA) therapy,
30–50% of patients with moderate or severe asthma remain inadequately controlled. We …

Background Severe asthma is characterized by difficulty to achieve disease control despite
high-intensity treatment. However, prevalence figures of severe asthma are lacking …

Background: The fractional exhaled nitric oxide (FeNO) test is a point-of-care test that is
used in the assessment of asthma. Objective: To provide evidence-based clinical guidance …

Rationale: IL-17 signaling has been implicated in development and persistence of asthma.
Cytokine-targeted strategies blocking IL-17 receptor signaling may be beneficial in asthma …